Fjarde AP Fonden Fourth Swedish National Pension Fund Buys 3,300 Shares of Moderna, Inc. (NASDAQ:MRNA)

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its stake in Moderna, Inc. (NASDAQ:MRNA) by 5.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 59,730 shares of the company’s stock after buying an additional 3,300 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Moderna were worth $2,484,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in MRNA. Intrinsic Value Partners LLC grew its position in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock worth $3,435,000 after purchasing an additional 24,505 shares in the last quarter. Banco Santander S.A. purchased a new stake in shares of Moderna during the third quarter worth about $3,550,000. John G Ullman & Associates Inc. grew its position in shares of Moderna by 341.3% during the third quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company’s stock worth $3,318,000 after purchasing an additional 38,400 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Moderna by 11.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares in the last quarter. Finally, abrdn plc grew its position in shares of Moderna by 28.1% during the fourth quarter. abrdn plc now owns 315,912 shares of the company’s stock worth $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 2,664 shares of company stock valued at $115,210. Insiders own 15.20% of the company’s stock.

Moderna Stock Performance

Shares of Moderna stock opened at $33.58 on Thursday. The stock has a market cap of $12.92 billion, a price-to-earnings ratio of -3.62 and a beta of 1.59. The stock has a 50 day moving average price of $37.74 and a 200-day moving average price of $51.74. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research analyst reports. Barclays cut Moderna from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Berenberg Bank raised their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Wolfe Research initiated coverage on Moderna in a report on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Finally, HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a report on Monday, November 18th. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.